Amicus Therapeutics (FOLD) are higher by more than 30% in mid-morning trading on Thursday, after the company announced that it will seek in the second half of this year accelerated U.S. approval for its Fabry disease therapy — Migalastat– following a productive meeting with the FDA. If approved, Migalastat will be the first oral therapy […] View the full post at: Amicus (FOLD) Shares Spike 30% Higher Related posts: Atlas Pipeline (APL) Shares Soar On Nat Gas Asset Sale Do the Benefits of Preventative Care Justify the Higher Spending?